Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CRMD with free AI briefings, catalyst countdowns, and dilution alerts.

CRMD · CorMedix Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$355.2M Cash on Hand
CF+ Cash Runway
Follow CRMD by email Get an email when CRMD reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CRMD, unsubscribe in one click. Privacy

📣 What CRMD Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Taurolidine And Heparin
FDA approved Nov 2023 · Defencath
Catheter-related Bloodstream Infection N/A · NCT06707480 No longer available
Taurolidine Catheter-Related Infections Phase 4 · NCT06714864 Recruiting
Heparin Central Line Associated Blood Stream Infections (CLABSI) Phase 3 · NCT06822426 Recruiting
Neutrolin Kidney Failure, Chronic Phase 3 · NCT02651428 Completed
CRMD-001-Deferiprone Contrast-Induced Acute Kidney Injury Phase 2 · NCT01146925 Completed

Also used in these trials (approved or third-party drugs, not CRMD's own candidates): Deferiprone.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CRMD holds $355.2M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CRMD files for a raise →

👥 Who Owns CRMD

Insiders 14.4% Other 5%+ holders 5.8% Institutions (267 holders) 57.2% Public and other holders 22.6%
HolderTypeShares% of sharesAs of
CorMedix Inc.
10% owner
Insider 9,090,909 11.43% 2025-09-07
Deep Track Capital, LP Institution (13G, 5%+) 6,274,076 7.89% 2026-03-31
SHAIBATALHAMD AYMEN ABDALKADER 5%+ holder (13G) 4,618,511 5.81% 2026-06-11
Joseph Todisco
Chief Executive Officer, Director · +997,912 options
Insider 854,749 1.07% 2026-11-13
Elizabeth Hurlburt
Chief Operating Officer
Insider 270,463 0.34% 2026-08-29
Myron Kaplan
Director
Insider 261,487 0.33% 2026-01-26
Kaufman Beth Zelnick
Chief Legal Officer · +150,000 options
Insider 260,684 0.33% 2026-08-29
Steven W Lefkowitz
Director
Insider 158,103 0.20% 2026-01-26
Michael David Seckler
Chief Commercial Officer
Insider 133,156 0.17% 2026-01-08
Susan Blum
Chief Financial Officer
Insider 124,315 0.16% 2026-08-29
Janet Dillione
Director · +5,000 options
Insider 117,835 0.15% 2026-09-18
Alan W Dunton
Director · +20,000 options
Insider 70,703 0.09% 2026-01-26

Share count 79,537,626 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CRMD picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CRMD and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.